NEW YORK, Sept. 23, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of results from an integrated safety analysis of UKONIQ ®  (umbralisib), the Company’s inhibitor of PI3k-delta and CK1-epsilon, in patients with relapsed or refractory lymphoid

Fireside chat scheduled for 10:40 AM ET on Monday, September 27, 2021 NEW YORK, Sept. 23, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in a fireside chat during the 2021

Investor & Analyst Virtual Event to Discuss Phase 1 U2 + Venetoclax Data to be held today, September 20, 2021 at 8:30 AM ET NEW YORK, Sept. 20, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data presentations at the XIX International Workshop on Chronic Lymphocytic

Investor & Analyst Virtual Event to Discuss Phase 1 U2 + Venetoclax Data to be held Monday, September 20, 2021 at 8:30 AM ET NEW YORK, Sept. 13, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today recapped the schedule of upcoming data presentations at the XIX International

Fireside chat available for on demand download at 7:00 AM ET on Monday, September 13, 2021 NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in a fireside

NEW YORK, Aug. 30, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of four data presentations at the upcoming XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL), being held virtually September 17 – 20, 2021.

Conference call to be held today, Monday, August 2, 2021 at 8:30 AM ET NEW YORK, Aug. 02, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the second quarter ending June 30, 2021 and recent company developments, along with a business outlook

Conference call to be held Monday, August 2, 2021 at 8:30 AM ET NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Monday, August 2, 2021 at 8:30 AM ET to discuss results for the second quarter 2021 and provide a

Fireside chat scheduled for Wednesday, July 14, 2021 at 12:30 PM ET NEW YORK, July 09, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in a fireside chat during the Ladenburg

NEW YORK, June 29, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced with great sadness the passing of longtime Board Member, William J. Kennedy, PhD. “It is with deep sorrow we announce the passing of Bill, one of the first Directors to join our board, and someone I